ArticleScientific reports2025
A panel of three serum microRNAs as a potential diagnostic biomarker for renal cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hitherto there is no praiseworthy noninvasive methods in the early diagnosis of renal cell carcinoma (RCC). MicroRNAs (miRNAs) could be utilized as molecular markers for diverse malignancies. In this study, we aim to discern potential miRNAs as markers for screening RCC. We employed quantitative reverse transcription-polymerase chain reaction (RT-qPCR) to detect expression levels of candidate miRNAs in serum specimens of 108 RCC patients and 112 health volunteers. Diagnostic values of miRNAs were appraised, and panel was constructed by dint of receiver operating characteristic curves, the area under the ROC curve and backward stepwise logistic regression analysis. Moreover, we capitalized on bioinformatics analysis for exploration of miRNAs biological functions. The expression of five miRNAs (miR-30c-5p, miR-142-3p, miR-206, miR-223-3p, miR-200c-5p) were markedly alteration in serum specimens of RCC patients and health subjects. A three-miRNA panel combining miR-30c-5p, miR-142-3p and miR-206 was constructed and could discriminate RCC patients and healthy subjects satisfactorily with 0.872 (0.811-0.919, P < 0.001) AUC, 81.25% sensitivity and 86.90% specificity. ATF3 and MYC seem to be potential targets of the three-miRNA panel. The novel miRNA-based panel may perform as potential noninvasive markers to discriminate RCC patients and healthy subjects in advance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.